Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. - Okada T; Sakaguchi T; Hatamura I; Saji F; Negi S; Otani H; Muragaki Y; Kawachi H; Shigematsu T (Clinical and experimental nephrology, 2009)